RESUMEN
OBJECTIVES: Covishield and Covaxin vaccines have been introduced after rapid approval in India, the nation that has the second most COVID-19 cases globally. These vaccines have been administered in a 2-dose schedule since January 16, 2021. This study deals with the clinical profile of individuals who developed COVID-19 infection post COVID-19 vaccination. This is the first study of its kind in India. STUDY DESIGN: Descriptive cross-sectional study. METHODS: The study population was composed of individuals who were COVID-19 positive more than 4 weeks post vaccination and were compared with individuals who were COVID-19 positive within the first 4 weeks of vaccination. Data were collected in a digital questionnaire format and analyzed with SPSS version 23 software. Clinical features were profiled in detail. Chi-square analysis was done to find out the association of various demographic features with the severity of the disease. RESULTS: In the study population, fever was the most common symptom (75.1%), followed by anosmia (72.1%) and shortness of breath (16.3%). There was a lower incidence of fever, cough, dyspnea, and requirement of hospitalization in the study population compared with the control group and previous epidemiological data. The time required for complete recovery and disease severity was favorable in our study population. There was a significant correlation in the rate of hospitalization among the study group and the comparative group (P = .0001) and between the number of doses of COVID-19 vaccine and the lowest oxygen saturation recorded (P = .001). CONCLUSIONS: The findings of this study should boost the ongoing initiative of maximizing the vaccinated population countrywide and emphasize the need for 2 doses of vaccination.
